IL302401A - Regimens for the treatment of hair loss disorders with faded JAC inhibitors - Google Patents

Regimens for the treatment of hair loss disorders with faded JAC inhibitors

Info

Publication number
IL302401A
IL302401A IL302401A IL30240123A IL302401A IL 302401 A IL302401 A IL 302401A IL 302401 A IL302401 A IL 302401A IL 30240123 A IL30240123 A IL 30240123A IL 302401 A IL302401 A IL 302401A
Authority
IL
Israel
Prior art keywords
compound
day
period
administered
pharmaceutically acceptable
Prior art date
Application number
IL302401A
Other languages
English (en)
Hebrew (he)
Inventor
James V Cassella
Original Assignee
Sun Pharmaceutical Ind Inc
James V Cassella
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Inc, James V Cassella filed Critical Sun Pharmaceutical Ind Inc
Publication of IL302401A publication Critical patent/IL302401A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL302401A 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with faded JAC inhibitors IL302401A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063106790P 2020-10-28 2020-10-28
US202163155637P 2021-03-02 2021-03-02
PCT/US2021/057123 WO2022094133A1 (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
IL302401A true IL302401A (en) 2023-06-01

Family

ID=78725692

Family Applications (1)

Application Number Title Priority Date Filing Date
IL302401A IL302401A (en) 2020-10-28 2021-10-28 Regimens for the treatment of hair loss disorders with faded JAC inhibitors

Country Status (14)

Country Link
US (1) US20230390292A1 (https=)
EP (1) EP4236956A1 (https=)
JP (1) JP2023553253A (https=)
KR (1) KR20230093504A (https=)
AU (1) AU2021372512A1 (https=)
CA (1) CA3196551A1 (https=)
CL (1) CL2023001201A1 (https=)
CO (1) CO2023006808A2 (https=)
DO (1) DOP2023000085A (https=)
IL (1) IL302401A (https=)
JO (1) JOP20230090A1 (https=)
MX (1) MX2023005027A (https=)
PE (1) PE20231945A1 (https=)
WO (1) WO2022094133A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3250876A1 (en) * 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. DOSAGE REGIMEN FOR TREATMENT WITH DEUTERATED JAK INHIBITORS
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造jak抑制劑之方法及相關中間化合物
HRP20250965T1 (hr) 2012-06-15 2025-10-10 Sun Pharmaceutical Industries, Inc. Deuterirani derivati ruksolitiniba
ES2988629T3 (es) * 2016-05-04 2024-11-21 Sun Pharmaceutical Ind Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados
AU2020219797B2 (en) 2019-02-06 2025-10-16 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched jak inhibitors
CA3228505A1 (en) * 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
CL2023001201A1 (es) 2023-11-17
US20230390292A1 (en) 2023-12-07
JOP20230090A1 (ar) 2023-04-27
MX2023005027A (es) 2023-07-31
CA3196551A1 (en) 2022-05-05
PE20231945A1 (es) 2023-12-05
AU2021372512A1 (en) 2023-06-22
KR20230093504A (ko) 2023-06-27
JP2023553253A (ja) 2023-12-21
EP4236956A1 (en) 2023-09-06
CO2023006808A2 (es) 2023-09-08
WO2022094133A9 (en) 2023-05-19
WO2022094133A1 (en) 2022-05-05
DOP2023000085A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
JP7196217B2 (ja) 重水素化されたcftr増強剤の投与
JP7586868B2 (ja) 重水素化jak阻害剤による脱毛障害の処置
AU2017352206B2 (en) Methods of treatment with deuterated CFTR potentiators
IL302401A (en) Regimens for the treatment of hair loss disorders with faded JAC inhibitors
JP2024531188A (ja) 重水素化jak阻害剤による脱毛障害の治療
KR20250126850A (ko) 탈모 장애의 치료 방법
OA21444A (en) Regimens For The Treatment Of Hair Loss Disorders With Deuterated Jak Inhibitors.
US20250275977A1 (en) Dosage regimens for treatment with deuterated jak inhibitors
CN116916927A (zh) 用于用氘化jak抑制剂治疗脱发症的方案
OA22110A (en) Dosage Regimens For Treatment With Deuterated Jak Inhibitors.
HK40112813A (en) Treatment of hair loss disorders with deuterated jak inhibitors
EA052710B1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
HK40002100A (en) Treatment of hair loss disorders with deuterated jak inhibitors